Skip to main content

Trevi Therapeutics, Inc. (TRVI)

NASDAQ: TRVI · IEX Real-Time Price · USD
1.35
+0.02 (1.50%)
After-hours:Oct 25, 2021 6:07 PM EDT
1.33
0.11 (9.02%)
At close: Oct 25, 4:00 PM
Market Cap34.35M
Revenue (ttm)n/a
Net Income (ttm)-35.07M
Shares Out20.12M
EPS (ttm)-1.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume779,782
Open1.25
Previous Close1.22
Day's Range1.22 - 1.36
52-Week Range1.10 - 3.98
Beta0.02
AnalystsBuy
Price Target10.00 (+651.9%)
Est. Earnings DateNov 10, 2021

About TRVI

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated...

IndustryPharmaceuticals
IPO DateMay 7, 2019
Employees23
Stock ExchangeNASDAQ
Ticker SymbolTRVI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for TRVI stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 651.88% from the latest price.

Price Target
$10.00
(651.88% upside)
Analyst Consensus: Buy

News

Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)

NEW HAVEN, Conn., Oct. 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigationa...

1 week ago - PRNewsWire

5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets

Will these penny stocks meet analysts' expectations? The post 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...

Other symbols:AIKINMTRPROGSELB
2 weeks ago - PennyStocks

Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference

NEW HAVEN, Conn., Oct. 7, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational...

2 weeks ago - PRNewsWire

Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market

NEW HAVEN, Conn., Sept. 30, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigationa...

3 weeks ago - PRNewsWire

Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update

NEW HAVEN, Conn., Aug. 12, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational...

2 months ago - PRNewsWire

Trevi Therapeutics Announces Additions to the Senior Leadership Team

NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational...

2 months ago - PRNewsWire

Trevi Therapeutics to Report Q2 2021 Financial Results on August 12

NEW HAVEN, Conn., Aug. 5, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational ...

2 months ago - PRNewsWire

Trevi Therapeutics to Present at 2021 BIO Digital Conference

NEW HAVEN, Conn., June 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational...

4 months ago - PRNewsWire

Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update

NEW HAVEN, Conn., May 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational...

5 months ago - PRNewsWire

Trevi Therapeutics to Report Q1 2021 Financial Results on May 13

NEW HAVEN, Conn., May 6, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational t...

5 months ago - PRNewsWire

Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nal...

6 months ago - GlobeNewsWire

Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates

Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021

7 months ago - GlobeNewsWire

Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25

Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET

7 months ago - GlobeNewsWire

Trevi Therapeutics' (TRVI) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Trevi Therapeutics (TRVI).

8 months ago - Zacks Investment Research

Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer

Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications

8 months ago - GlobeNewsWire

Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q3 2020 Results - Earnings Call Transcript

Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q3 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update

PRISM Trial of Haduvio ™ for Severe Pruritus in Patients with Prurigo Nodularis 

11 months ago - GlobeNewsWire

Trevi Therapeutics to Present at Stifel Healthcare Conference

NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalb...

11 months ago - GlobeNewsWire

Trevi Therapeutics to Report Q3 2020 Financial Results on November 11

Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET

11 months ago - GlobeNewsWire

Trevi Therapeutics Announces the Hiring of Key Talent

Expands Management Team to Support Clinical Development and Commercial Strategy of Haduvio™ in Multiple Late Stage Programs Expands Management Team to Support Clinical Development and Commercial Strateg...

1 year ago - GlobeNewsWire

Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference

NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (n...

1 year ago - GlobeNewsWire

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2020 Results - Earnings Call Transcript

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Trevi Therapeutics Announces Second Quarter 2020 Financial Results and Business Update

Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial

1 year ago - GlobeNewsWire

Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference

NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (na...

1 year ago - GlobeNewsWire

Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pru...

Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design

1 year ago - GlobeNewsWire